搜索
Amarin Corporation PLC
AMRN添加自选
16.370USD
-0.100-0.61%
收盘 07/02, 13:00（美东）报价延迟15分钟
343.44M总市值
亏损市盈率 TTM
关键数据
16.640今开
16.790最高
91.70K成交量
亏损市盈率 TTM
12.25市盈率动
--股息TTM
0.44%换手率
16.470昨收
16.180最低
1.06M成交额
亏损市盈率静
0.76市净率
0.00%股息率 TTM
-5.17%ROA
20.90052周最高
1.81量比
-82.18M净利润
20.98M总股本
-1.6122每股收益TTM
0.82Beta
-7.28%ROE
11.27052周最低
3.70%振幅
36.84%毛利率
343.44M总市值
7.07回报/风险
2.74%风险率
TradingKey Amarin Corporation PLC股票评分
单位: USD 更新时间: 2026-07-02操作建议
Amarin Corporation PLC当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名113/387位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价12.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Amarin Corporation PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Amarin Corporation PLC亮点
亮点风险
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
分析师目标
根据
2
位分析师
持有
评级
12.000
目标均价
-27.14%
涨幅空间
Amarin Corporation PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Amarin Corporation PLC简介
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
公司代码AMRN
公司Amarin Corporation PLC
CEOBerg (Aaron D)
网址https://amarincorp.com/
相关品种
热门品种
常见问题
Amarin Corporation PLC(AMRN)的当前股价是多少？
Amarin Corporation PLC(AMRN)的当前股价是 16.37。
Amarin Corporation PLC的股票代码是什么？
Amarin Corporation PLC的股票代码是AMRN。
Amarin Corporation PLC股票的52周最高点是多少？
Amarin Corporation PLC股票的52周最高点是20.90。
Amarin Corporation PLC股票的52周最低点是多少？
Amarin Corporation PLC股票的52周最低点是11.27。
Amarin Corporation PLC的市值是多少？
Amarin Corporation PLC的市值是340.67M。
现在Amarin Corporation PLC(AMRN)的股票是买入、持有还是卖出？
根据分析师评级，Amarin Corporation PLC(AMRN)的总体评级为signal_hold，目标价格为12.00。
Amarin Corporation PLC(AMRN)股票的每股收益（EPS TTM）是多少
Amarin Corporation PLC(AMRN)股票的每股收益（EPS TTM）是-37.40。